2018
The safe use of Doliocarpus dentatus in the gestational period: Absence of changes in maternal reproductive performance, embryo-fetal development and DNA integrity
Ishikawa R, Vani J, das Neves S, Rabacow A, Kassuya C, Croda J, Cardoso C, Monreal A, Antoniolli A, Cunha-Laura A, Oliveira R. The safe use of Doliocarpus dentatus in the gestational period: Absence of changes in maternal reproductive performance, embryo-fetal development and DNA integrity. Journal Of Ethnopharmacology 2018, 217: 1-6. PMID: 29408581, DOI: 10.1016/j.jep.2018.01.034.Peer-Reviewed Original ResearchConceptsFemale Swiss miceDoliocarpus dentatusSwiss miceEmbryofetal developmentGestational periodControl groupPregnant female Swiss miceEnd of pregnancyEmbryo-fetal developmentMaternal reproductive performanceReproductive performanceSafe useEmbryofoetal developmentUrinary retentionOral gavageAbsence of changesDNA integrityAntimycobacterial actionFetal developmentReproductive parametersFormation of micronucleiEthanolic extractPregnancySignificant differencesExperimental group
2016
Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition
Hubers SA, Brown NJ. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition. Circulation 2016, 133: 1115-1124. PMID: 26976916, PMCID: PMC4800749, DOI: 10.1161/circulationaha.115.018622.Peer-Reviewed Original ResearchMeSH KeywordsAbnormalities, Drug-InducedAminobutyratesAngioedemaAngiotensin Receptor AntagonistsBiphenyl CompoundsBradykininContraindicationsDrug CombinationsDrug CostsDrug SynergismEnalaprilEnzyme InhibitorsFemaleFollow-Up StudiesHeart FailureHumansHyperkalemiaHypertensionKidneyMulticenter Studies as TopicNatriuretic PeptidesNeprilysinPregnancyProdrugsProspective StudiesPyridinesRandomized Controlled Trials as TopicStroke VolumeTetrazolesThiazepinesValsartanConceptsValsartan/sacubitrilReduced ejection fractionHeart failureNatriuretic peptideEjection fractionN-terminal pro-brain natriuretic peptideNeprilysin inhibitor prodrug sacubitrilPro-brain natriuretic peptideAngiotensin receptor blocker valsartanAngiotensin receptor antagonismAngiotensin receptor blockersHeart Failure TrialReceptor blocker valsartanAngiotensin receptor antagonistsBrain natriuretic peptideOngoing clinical trialsMechanism of actionNeprilysin inhibitionAldosterone antagonistsAldosterone systemReceptor blockersBlood pressureFailure TrialPathophysiological mechanismsReceptor antagonism
2015
Case–control studies require appropriate population controls: an example of error in the SSRI birth defect literature
Bracken MB. Case–control studies require appropriate population controls: an example of error in the SSRI birth defect literature. European Journal Of Epidemiology 2015, 30: 1217-1218. PMID: 26518772, DOI: 10.1007/s10654-015-0097-3.Commentaries, Editorials and LettersObstetric and Neonatal Outcomes After Antipsychotic Medication Exposure in Pregnancy
Coughlin CG, Blackwell KA, Bartley C, Hay M, Yonkers KA, Bloch MH. Obstetric and Neonatal Outcomes After Antipsychotic Medication Exposure in Pregnancy. Obstetrics And Gynecology 2015, 125: 1224-1235. PMID: 25932852, PMCID: PMC4418034, DOI: 10.1097/aog.0000000000000759.Peer-Reviewed Original ResearchConceptsAdverse birth outcomesGestational-age birthsAntipsychotic exposureNeonatal outcomesCohort studyBirth outcomesAntipsychotic medicationMajor malformationsBirth weightOdds ratioAntipsychotic medication exposureNeonatal birth weightPooled odds ratioPotential risk factorsUnexposed pregnanciesMedication exposurePreterm deliveryGestational ageAntipsychotic treatmentElective terminationPossible confoundersReproductive ageRisk factorsSpontaneous abortionSTUDY SELECTION
2013
Counseling of Female Veterans About Risks of Medication-Induced Birth Defects
Schwarz EB, Mattocks K, Brandt C, Borrero S, Zephyrin LC, Bathulapalli H, Haskell S. Counseling of Female Veterans About Risks of Medication-Induced Birth Defects. Journal Of General Internal Medicine 2013, 28: 598-603. PMID: 23807071, PMCID: PMC3695268, DOI: 10.1007/s11606-012-2240-0.Peer-Reviewed Original ResearchConceptsMedication-induced birth defectsFemale veteransTeratogenic riskPrescription medicationsBirth defectsHealthcare providersHealth services utilization variablesPARTICIPANTSCross-sectional analysisResultsThe response rateHealth care providersService utilization variablesKey ResultsThe response rateReceipt of counselingVeterans' receiptMedication useReproductive ageAppropriate counselingCare providersMedicationsOperation Enduring FreedomRisk counselingVA pharmacyResponse rateUtilization variablesSuch counseling
2004
NTP‐CERHR Expert Panel Report on the reproductive and developmental toxicity of fluoxetine
Hines R, Adams J, Buck G, Faber W, Holson J, Jacobson S, Keszler M, McMartin K, Segraves R, Singer L, Sipes I, Williams P. NTP‐CERHR Expert Panel Report on the reproductive and developmental toxicity of fluoxetine. Birth Defects Research Part B Developmental And Reproductive Toxicology 2004, 71: 193-280. PMID: 15334524, DOI: 10.1002/bdrb.20014.Peer-Reviewed Original ResearchAbnormalities, Drug-InducedAnimalsFluoxetineHumansInfant, NewbornInfant, Newborn, DiseasesReproduction
1997
Multiple congenital anomalies associated with weekly low‐dose methotrexate treatment of the mother
Buckley L, Bullaboy C, Leichtman L, Marquez M. Multiple congenital anomalies associated with weekly low‐dose methotrexate treatment of the mother. Arthritis & Rheumatism 1997, 40: 971-973. PMID: 9153561, DOI: 10.1002/art.1780400527.Peer-Reviewed Original ResearchMeSH KeywordsAbnormalities, Drug-InducedAdultArthritis, JuvenileBone and BonesFemaleFetal Growth RetardationHeart MurmursHumansMaternal-Fetal ExchangeMethotrexatePregnancyConceptsWeekly low-dose methotrexateLow-dose methotrexateMultiple congenital anomaliesCongenital anomaliesLow-dose MTX treatmentLow-dose methotrexate treatmentJuvenile rheumatoid arthritisFirst case reportGroup of abnormalitiesMultiple congenital abnormalitiesMethotrexate treatmentMTX treatmentRheumatoid arthritisFirst trimesterCase reportMaternal ingestionSpontaneous abortionCongenital abnormalitiesMethotrexateDosage levelsAbnormalitiesMothersAbortionTreatmentReport
1992
Effect of Cocaine Use on the Fetus
Kain Z, Kain T, Scarpelli E. Effect of Cocaine Use on the Fetus. New England Journal Of Medicine 1992, 327: 1393-1394. PMID: 1406850, DOI: 10.1056/nejm199211053271917.Peer-Reviewed Original ResearchReproductive Effects of Caffeine: A Review and Theoretical Analysis
Dlugosz L, Bracken M. Reproductive Effects of Caffeine: A Review and Theoretical Analysis. Epidemiologic Reviews 1992, 14: 83-100. PMID: 1289118, DOI: 10.1093/oxfordjournals.epirev.a036093.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCocaine Exposure in utero: Perinatal Development and Neonatal Manifestations - Review
Kain Z, Kain T, Scarpelli E. Cocaine Exposure in utero: Perinatal Development and Neonatal Manifestations - Review. Journal Of Toxicology Clinical Toxicology 1992, 30: 607-636. PMID: 1433431, DOI: 10.3109/15563659209017946.Peer-Reviewed Original ResearchConceptsCocaine exposureTeratogenic effectsProspective human studiesMonths of pregnancyIllicit drugsMost animal studiesMajor structural malformationsPrenatal careHuman studiesAnimal studiesStructural malformationsFetal developmentPerinatal developmentCocaine useLittle specific informationHuman dataPregnancyUteroExposureDrugsAbnormalitiesMalformationsCareCocaineMonths
1986
Congenital heart disease and extracardiac anomalies: Associations and indications for fetal echocardiography
Copel J, Pilu G, Kleinman C. Congenital heart disease and extracardiac anomalies: Associations and indications for fetal echocardiography. American Journal Of Obstetrics And Gynecology 1986, 154: 1121-1132. PMID: 2939723, DOI: 10.1016/0002-9378(86)90773-8.Peer-Reviewed Original ResearchMeSH KeywordsAbdominal MusclesAbnormalities, Drug-InducedAbnormalities, MultipleCentral Nervous SystemChromosome AberrationsChromosome DisordersCongenital AbnormalitiesDigestive System AbnormalitiesEchocardiographyFemaleFetal HeartHeart Defects, CongenitalHumansInfant, NewbornPhenylketonuriasPregnancyPregnancy ComplicationsPregnancy in DiabeticsPrenatal DiagnosisRespiratory System AbnormalitiesUrogenital AbnormalitiesConceptsCongenital heart diseaseHeart diseaseExtracardiac anomaliesFetal echocardiographyCardiac evaluationMaternal diabetesNeonatal managementDiaphragmatic herniaDuodenal atresiaPediatric literatureRenal dysplasiaCorpus callosumDifferential diagnosisEsophageal atresiaMeckel-Gruber syndromeReported associationsEchocardiographyPrenatal identificationSystemic defectsDiseaseAtresiaCoexistent defectsAssociationIndicationsDiabetes
1985
Spermicidal contraceptives and poor reproductive outcomes: The epidemiologic evidence against an association
Bracken M. Spermicidal contraceptives and poor reproductive outcomes: The epidemiologic evidence against an association. American Journal Of Obstetrics And Gynecology 1985, 151: 552-556. PMID: 3883778, DOI: 10.1016/0002-9378(85)90137-1.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAbnormalities, Drug-InducedAbortion, IncompleteEpidemiologic MethodsFemaleHumansInfant, Low Birth WeightInfant, NewbornPregnancyPublic PolicyRiskSpermatocidal AgentsUnited StatesConceptsPoor reproductive outcomesRecent epidemiologic studiesEpidemiologic evidenceObstetric practiceSpontaneous abortionSpermicidal contraceptivesEpidemiologic studiesReproductive outcomesCongenital malformationsAvailable evidenceSuch associationsContraceptionAssociationContraceptivesMalformations
1982
Bendectin (Debendox) as a risk factor for pyloric stenosis
Eskenazi B, Bracken M. Bendectin (Debendox) as a risk factor for pyloric stenosis. American Journal Of Obstetrics And Gynecology 1982, 144: 919-924. PMID: 7148924, DOI: 10.1016/0002-9378(82)90185-5.Peer-Reviewed Original ResearchConceptsPyloric stenosisCongenital malformationsMaternal sociodemographic factorsMothers of infantsCase-control studyHeart valve anomaliesFirst trimesterValve anomaliesMaternal useRisk factorsMalformed infantsSociodemographic factorsPossible associationSignificant associationStenosisInfantsStrong associationBirth defectsBendectinMothersMalformationsAssociationTrimesterSmokingPregnancy
1978
Role of Oral Contraception in Congenital Malformations of Offspring
BRACKEN M, HOLFORD T, WHITE C, KELSEY J. Role of Oral Contraception in Congenital Malformations of Offspring. International Journal Of Epidemiology 1978, 7: 309-317. PMID: 744667, DOI: 10.1093/ije/7.4.309.Peer-Reviewed Original ResearchMeSH KeywordsAbnormalities, Drug-InducedAdultContraceptives, OralFemaleHumansInfant, NewbornPregnancyRiskSmokingTime FactorsConceptsOral contraceptivesCongenital malformationsHealthy control infantsOral contraceptive useCase-control studyTime of conceptionOccurrence of malformationsControl infantsMaternal exposureOral contraceptionContraceptive useMalformed infantsSpecific estrogenSpecific diagnosisControl studyPregnancyMalformationsContraceptivesCardiovascular defectsInfantsExposureWomenProgestogensOffspringEstrogen
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply